SCHEMBL8308396

SCHEMBL8308396

O=C1NC(=O)C(Cc2ccc(OCCN3CC(c4cccc(Cl)c4)OC3=O)cc2)S1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 13/20 0.54
PPARG P37231 7/20 0.54
HRH3 Q9Y5N1 1/20 0.51
PPARA Q07869 2/20 0.46
MPC2 O95563 1/20 0.44
CYP2C8 P10632 1/20 0.44
CYP2C9 P11712 1/20 0.44
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9440663 0.96 HRH3 (0.55) FFAR1PPARGHRH3PPARAMPC2
SCHEMBL8304663 0.89 HRH3 (0.56) FFAR1PPARGHRH3PPARAMEN1
SCHEMBL9440668 0.87 FFAR1 (0.46) FFAR1PPARGHRH3PPARAMPC2
SCHEMBL8975030 0.85 FFAR1 (0.52) FFAR1PPARGHRH3PPARAMPC2
SCHEMBL8303956 0.83 PPARG (0.48) FFAR1PPARGHRH3PPARAMPC2
SCHEMBL8303702 0.83 PPARG (0.48) FFAR1PPARGHRH3PPARAMPC2
SCHEMBL8309318 0.81 PPARG (0.46) FFAR1PPARGHRH3PPARAMPC2
SCHEMBL8309316 0.81 PPARG (0.46) FFAR1PPARGHRH3PPARAMPC2
SCHEMBL8974565 0.80 FFAR1 (0.49) FFAR1PPARGHRH3PPARAMPC2
SCHEMBL8307509 0.79 PPARG (0.47) FFAR1PPARGHRH3PPARAMPC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0590793-B1 Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO CO (JP) 1999-10-13 EP disclosed
US-5436257-A Low toxicity SANKYO COMPANY, LIMITED (JP) 1995-07-25 US disclosed
EP-0590793-A1 Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1994-04-06 EP disclosed